Business Cycle
Clinical Laserthermia Systems sits in the early ramp phase of its cycle. Third-quarter revenue increased 80 percent year on year to SEK 5.0 million while gross margin remained above 60 percent, but January–September revenue stayed 16 percent below the prior year after a weak start during discussions with the neurosurgery partner. The company continues to expect double-digit revenue growth for full-year 2026 compared with 2025.
Site activation and the buildup of procedure volumes require time, so revenue can vary between quarters.
Growth Drivers
Clinical Laserthermia Systems' partnership-led neurosurgery strategy is yielding a steady flow of Prism product deliveries and an 80 percent jump in third-quarter revenue, and the company expects double-digit revenue growth across the full 2026 year relative to 2025. Third-quarter revenue reached SEK 5.0 million, while gross margin stayed above 60 percent. This steady Prism flow marks the company's return to year-on-year revenue growth.
Clinical Laserthermia Systems entered a strategic partnership agreement with advanced fiber tools GmbH to jointly pursue new commercial opportunities, pairing its proprietary non-cooled laser technology with AFT's fiber-optic engineering and manufacturing expertise. The two firms plan to develop specialized therapeutic medical laser products for a wide range of markets outside the company's current neurosurgery and urology partnerships.
The USD 2.98 million program seeks to advance MR-guided LITT for spinal metastases from laboratory and preclinical validation into clinical evaluation. The updated AES/CNS epilepsy surgery guideline, published in October, further strengthens the clinical framework for LITT in defined patient groups with drug-resistant epilepsy.
Market Outlook
Focal therapy adoption moves in Clinical Laserthermia Systems' favor because Grand View Research projects the global prostatic ablation devices market to expand at a 14.0% CAGR from USD 2.5 billion in 2026 to USD 6.3 billion by 2033, after estimating USD 2.2 billion in 2025, while guidelines still regard focal therapy as experimental. Focal therapy has drawn growing attention from patients and physicians over several years.
The market is primarily driven by the rising prevalence of localized prostate cancer and benign prostatic hyperplasia, coupled with increasing demand for minimally invasive treatment options that reduce hospital stays and preserve urinary and sexual function.
An updated AES/CNS epilepsy surgery guideline published in October further strengthens the clinical framework for laser interstitial thermal therapy in defined groups of patients with drug-resistant epilepsy.
Risk Factors
Clinical Laserthermia Systems' revenue recovery is fragile: revenue for January–September remained 16 percent below last year after a weak start during discussions with its neurosurgery partner. The 2026 outlook assumes the Company completes planned financing activities, which would provide financial flexibility needed to carry out its accelerated commercialization strategy and meet known financial commitments. The issued TO 9 B warrants offer a potential additional capital source in March 2027, with proceeds contingent on the extent to which holders exercise them.
The time needed to activate sites and grow procedure volumes means revenue can vary between quarters. Clinical Laserthermia Systems' immediate focus covers supporting commercial execution in the U.S and advancing the regulatory work needed for European market access.
Clinical Laserthermia Systems completed a rights issue of units that was subscribed to approximately 78.5 percent including subscription and guarantee undertakings, raising approximately SEK 31 million before transaction-related costs.
